Printer Friendly

U.S. BIOSCIENCE ANNOUNCES STOCK SPLIT

 U.S. BIOSCIENCE ANNOUNCES STOCK SPLIT
 WEST CONSHOHOCKEN, Pa., Dec. 16 /PRNewswire/ -- The board of


directors of U.S. Bioscience Inc. (AMEX: UBS) today has declared a two-for-one split of the company's common stock in the form of a 100 percent stock dividend, payable on Jan. 16, 1992, to shareholders of record as of the close of business Dec. 26, 1991.
 U.S. Bioscience currently has approximately 19.6 million shares of common stock outstanding, which will now be doubled as a result of the split. Correspondingly, the share price will be reduced by approximately half so that there is no tax or economic impact on shareholders from this transaction. The company is authorized to issue 50 million shares of common stock, and due to the stock split, it is anticipated that this authorization will be proposed for increase at the company's next annual meeting.
 Based in West Conshohocken, U.S. Bioscience is a pharmaceutical company specializing in the development and commercialization of products to increase the survival and quality of life for patients with cancer and allied diseases.
 -0- 12/16/91
 /CONTACT: Robert I. Kriebel of U.S. Bioscience, 215-832-4503, or Charles Versaggi of Versaggi & Associates, 408-358-4162 or 408-395-1877 for U.S. Bioscience/
 (UBS) CO: U.S. Bioscience Inc. ST: California IN: MTC SU:


DB -- SJ003 -- 2350 12/16/91 08:31 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 16, 1991
Words:225
Previous Article:AMEV HOLDINGS TO CHANGE NAME TO FORTIS, INC.; NEW CORPORATE NAMES ADOPTED FOR WESTERN LIFE, MBL GROUP, FOUR OTHER AMEV SUBSIDIARIES
Next Article:SILICON GRAPHICS LAUNCHES IRIS PARTNERS PROGRAM
Topics:


Related Articles
U.S. BIOSCIENCE GRANTS SCHERING-PLOUGH MARKETING RIGHTS TO PRODUCTS IN LATIN AMERICA AND FAR EAST
U.S. BIOSCIENCE ANNOUNCES STOCK SPLIT
TRADING OF U.S. BIOSCIENCE STOCK SUSPENDED PENDING CONCLUSION OF FDA COMMITTEE REVIEW
U.S. BIOSCIENCE REPORTS FOURTH QUARTER RESULTS OF OPERATIONS
U.S. BIOSCIENCE REJECTS INACCURATE REPORTS ON ETHYOL(R)
U.S. BIOSCIENCE REJECTS INACCURATE REPORTS ON ETHYOL(R)
AMEX TO TRADE OPTIONS ON U.S. BIOSCIENCE, INC.
MedImmune, Inc. to Acquire U.S. Bioscience, Inc. -Acquisition Provides Immediate Products and Infrastructure in Oncology-.
MedImmune to Exchange 0.15 Shares for Each U.S. Bioscience Share in Proposed Acquisition.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters